|Systematic (IUPAC) name|
|Mol. mass||329.265 g/mol|
|(what is this?)|
AH-7921 is an opioid analgesic drug selective for the µ-opioid receptor, having around 80% the potency of morphine when administered orally. It was discovered in the 1970s by a team at Allen and Hanburys.
Dosages have been reported to range from as little as 10 mg to around 200 mg or higher (for opioid-tolerant individuals). This would confirm the previous studies of AH-7921 being roughly 80% as potent as morphine.
A trivial name(s) doxylam has been proposed for this compound, but it has never been never sold commercially for medical use. In 2013 AH-7921 was discovered to have been used as an active ingredient in "synthetic cannabis" products in Japan.
- Brittain, R. T.; Kellett, D. N.; Neat, M. L.; Stables, R. (1973). "Proceedings: Anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides". British Journal of Pharmacology 49 (1): 158P–159P. PMC 1776456. PMID 4207044.
- Hayes, A. G.; Tyers, M. B. (1983). "Determination of receptors that mediate opiate side effects in the mouse". British Journal of Pharmacology 79 (3): 731–736. PMC 2044905. PMID 6317119.
- US patent 3975443, Harper, N.; Veitch, G., "1-(3,4-DICHLOROBENZAMIDOMETHYL)-CYCLOHEXYLDIMETHYLAMINE", issued 1976-08-17, assigned to Allen & Hanburys
- Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. doi:10.1007/s11419-013-0182-9.
|This analgesic-related article is a stub. You can help Wikipedia by expanding it.|